Axonics Inc (AXNX) Stock Fundamental Analysis
USA - NASDAQ:AXNX - US05465P1012 - Common Stock
70.98 USD
+0.53 (+0.75%)
70.98 USD
0 (0%)
We assign a fundamental rating of 5 out of 10 to AXNX. AXNX was compared to 189 industry peers in the Health Care Equipment & Supplies industry. No worries on liquidiy or solvency for AXNX as it has an excellent financial health rating, but there are worries on the profitability. AXNX is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
AXNX had negative earnings in the past year.
In the past year AXNX had a positive cash flow from operations.
In the past 5 years AXNX always reported negative net income.
In the past 5 years AXNX reported 4 times negative operating cash flow.
1.2 Ratios
The Return On Assets of AXNX (-0.73%) is better than 67.91% of its industry peers.
With a decent Return On Equity value of -0.85%, AXNX is doing good in the industry, outperforming 68.98% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.73% | ||
| ROE | -0.85% | ||
| ROIC | N/A |
ROA(3y)-8.17%
ROA(5y)-15.38%
ROE(3y)-9.34%
ROE(5y)-18.16%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 76.59%, AXNX belongs to the top of the industry, outperforming 89.30% of the companies in the same industry.
In the last couple of years the Gross Margin of AXNX has grown nicely.
The Profit Margin and Operating Margin are not available for AXNX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 76.59% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.58%
GM growth 5Y5.57%
2. Health
2.1 Basic Checks
AXNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AXNX has more shares outstanding
Compared to 5 years ago, AXNX has more shares outstanding
AXNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
AXNX has an Altman-Z score of 20.38. This indicates that AXNX is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 20.38, AXNX belongs to the best of the industry, outperforming 93.58% of the companies in the same industry.
There is no outstanding debt for AXNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 20.38 |
ROIC/WACCN/A
WACC9.07%
2.3 Liquidity
A Current Ratio of 8.16 indicates that AXNX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 8.16, AXNX belongs to the top of the industry, outperforming 87.70% of the companies in the same industry.
A Quick Ratio of 6.40 indicates that AXNX has no problem at all paying its short term obligations.
AXNX has a Quick ratio of 6.40. This is amongst the best in the industry. AXNX outperforms 85.03% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.16 | ||
| Quick Ratio | 6.4 |
3. Growth
3.1 Past
The earnings per share for AXNX have decreased strongly by -116.67% in the last year.
Looking at the last year, AXNX shows a very strong growth in Revenue. The Revenue has grown by 26.08%.
Measured over the past years, AXNX shows a very strong growth in Revenue. The Revenue has been growing by 249.76% on average per year.
EPS 1Y (TTM)-116.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)26.08%
Revenue growth 3Y48.67%
Revenue growth 5Y249.76%
Sales Q2Q%24.8%
3.2 Future
AXNX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 69.51% yearly.
The Revenue is expected to grow by 19.14% on average over the next years. This is quite good.
EPS Next Y56.54%
EPS Next 2Y120.11%
EPS Next 3Y100.31%
EPS Next 5Y69.51%
Revenue Next Year23.72%
Revenue Next 2Y21.8%
Revenue Next 3Y20.53%
Revenue Next 5Y19.14%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for AXNX. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 81.39, which means the current valuation is very expensive for AXNX.
Based on the Price/Forward Earnings ratio, AXNX is valued a bit cheaper than the industry average as 65.78% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 34.57. AXNX is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 81.39 |
4.2 Price Multiples
62.57% of the companies in the same industry are more expensive than AXNX, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of AXNX indicates a somewhat cheap valuation: AXNX is cheaper than 66.84% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 675.06 | ||
| EV/EBITDA | 603.04 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as AXNX's earnings are expected to grow with 100.31% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y120.11%
EPS Next 3Y100.31%
5. Dividend
5.1 Amount
AXNX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
70.98
+0.53 (+0.75%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners85.44%
Inst Owner Change0%
Ins Owners5.35%
Ins Owner Change0%
Market Cap3.63B
Revenue(TTM)431.90M
Net Income(TTM)-5.66M
Analysts68.42
Price Target73.33 (3.31%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-50.5%
Min EPS beat(2)-100%
Max EPS beat(2)-1.01%
EPS beat(4)1
Avg EPS beat(4)-49.29%
Min EPS beat(4)-215.13%
Max EPS beat(4)118.99%
EPS beat(8)5
Avg EPS beat(8)52.84%
EPS beat(12)9
Avg EPS beat(12)41.69%
EPS beat(16)11
Avg EPS beat(16)30.84%
Revenue beat(2)2
Avg Revenue beat(2)0.21%
Min Revenue beat(2)0.05%
Max Revenue beat(2)0.37%
Revenue beat(4)3
Avg Revenue beat(4)0.07%
Min Revenue beat(4)-0.36%
Max Revenue beat(4)0.37%
Revenue beat(8)7
Avg Revenue beat(8)1.85%
Revenue beat(12)11
Avg Revenue beat(12)3.83%
Revenue beat(16)13
Avg Revenue beat(16)4.5%
PT rev (1m)0.23%
PT rev (3m)0.23%
EPS NQ rev (1m)21.53%
EPS NQ rev (3m)21.53%
EPS NY rev (1m)-2.83%
EPS NY rev (3m)5.04%
Revenue NQ rev (1m)0.94%
Revenue NQ rev (3m)0.94%
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)0.23%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 81.39 | ||
| P/S | 8.4 | ||
| P/FCF | 675.06 | ||
| P/OCF | 253.73 | ||
| P/B | 5.46 | ||
| P/tB | 7.53 | ||
| EV/EBITDA | 603.04 |
EPS(TTM)-0.01
EYN/A
EPS(NY)0.87
Fwd EY1.23%
FCF(TTM)0.11
FCFY0.15%
OCF(TTM)0.28
OCFY0.39%
SpS8.45
BVpS13
TBVpS9.42
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.73% | ||
| ROE | -0.85% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 76.59% | ||
| FCFM | 1.24% |
ROA(3y)-8.17%
ROA(5y)-15.38%
ROE(3y)-9.34%
ROE(5y)-18.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.58%
GM growth 5Y5.57%
F-Score6
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 71.48% | ||
| Cap/Sales | 2.07% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 271.41% | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.16 | ||
| Quick Ratio | 6.4 | ||
| Altman-Z | 20.38 |
F-Score6
WACC9.07%
ROIC/WACCN/A
Cap/Depr(3y)24.04%
Cap/Depr(5y)70.74%
Cap/Sales(3y)1.01%
Cap/Sales(5y)3.08%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-116.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y56.54%
EPS Next 2Y120.11%
EPS Next 3Y100.31%
EPS Next 5Y69.51%
Revenue 1Y (TTM)26.08%
Revenue growth 3Y48.67%
Revenue growth 5Y249.76%
Sales Q2Q%24.8%
Revenue Next Year23.72%
Revenue Next 2Y21.8%
Revenue Next 3Y20.53%
Revenue Next 5Y19.14%
EBIT growth 1Y33.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year377.96%
EBIT Next 3Y82.88%
EBIT Next 5Y66.14%
FCF growth 1Y133.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y210.5%
OCF growth 3YN/A
OCF growth 5YN/A
Axonics Inc / AXNX FAQ
What is the ChartMill fundamental rating of Axonics Inc (AXNX) stock?
ChartMill assigns a fundamental rating of 5 / 10 to AXNX.
What is the valuation status for AXNX stock?
ChartMill assigns a valuation rating of 4 / 10 to Axonics Inc (AXNX). This can be considered as Fairly Valued.
Can you provide the profitability details for Axonics Inc?
Axonics Inc (AXNX) has a profitability rating of 3 / 10.